Chemotherapy regimens

Which Regimen Is Used — for Which Cancer?

A regimen name on your chart is shorthand for a specific combination of drugs. This page decodes the most common acronyms and explains how each one is matched to a cancer type and stage.

Every acronym names real drugs — FOLFOX, AC, R-CHOP — each letter stands for a drug or drug class in the combination.
The match is evidence-based — Your oncologist chooses from regimens endorsed by NCCN, ESMO, or ICMR for your specific cancer type and stage.
Your biology matters — Kidney function, heart function, and molecular markers all narrow the list of regimens that are safe and appropriate for you.
It can change — Regimens are reviewed after each response assessment and can be adjusted if the cancer or your tolerance changes.

Medically reviewed by Dr. N. Kiranmayee, Medical Oncologist · Last reviewed September 2026

Prescription-only medicine. All chemotherapy regimens are prescription-only medicines that must be given under the direct supervision of an oncologist. Nothing on this page can be used to start, change or stop any treatment. Decisions about which regimen is right for you are made by a specialist based on your individual diagnosis, test results and clinical history. Nothing on this page is a recommendation to use this medicine. It is not suitable for most patients — see "Who this is not for" below.

Chemotherapy regimens are matched to cancer type, stage, and molecular subtype. FOLFOX is used in colorectal cancer; R-CHOP in B-cell lymphoma; ABVD in Hodgkin lymphoma; AC in breast cancer. Your oncologist selects the regimen that NCCN, ESMO, or ICMR guidelines support for your specific diagnosis and the results of your staging and biomarker tests.

What does each acronym actually mean?

AC: Doxorubicin (brand name Adriamycin) and cyclophosphamide. Used in breast cancer, often followed by a taxane such as paclitaxel or docetaxel.
FOLFOX: Fluorouracil, leucovorin, and oxaliplatin. Leucovorin enhances the action of fluorouracil. Used in colorectal cancer.
FOLFIRI: Fluorouracil, leucovorin, and irinotecan. Used in colorectal cancer, particularly when oxaliplatin is not suitable.
CAPOX (also written XELOX): Capecitabine and oxaliplatin. Capecitabine is an oral tablet that converts to fluorouracil inside the body, making this regimen partially oral. Used in colorectal and gastric cancers.
R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. Rituximab is a targeted antibody added to the CHOP backbone. Used in B-cell lymphomas, including diffuse large B-cell lymphoma.
ABVD: Doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine. The standard regimen for Hodgkin lymphoma.
BEP: Bleomycin, etoposide, and cisplatin. Used in testicular cancer and other germ cell tumours.
Carbo-Taxol: Carboplatin and paclitaxel (brand name Taxol). Used in lung, ovarian, endometrial, and other cancers depending on the specific indication and stage.
GemCis: Gemcitabine and cisplatin. Used in lung, bladder, biliary, and pancreatic cancers, depending on the context and stage.

How does your oncologist choose your regimen?

Confirm the diagnosis
Pathology from your biopsy establishes the cancer type, grade, and molecular subtype — the foundation for every treatment decision.
Complete staging
Imaging establishes how far the cancer has spread, which changes both the treatment goal and the regimen choices available.
Run biomarker tests
Tumour tissue may be tested for HER2, hormone receptors, microsatellite instability, or other markers that predict which drugs are active for your specific tumour.
Assess organ function
Blood tests for kidney and liver function, and sometimes a heart scan, determine which drugs are safe for you at this point in time.
Match to guidelines
The oncologist selects from the regimens that NCCN, ESMO, or ICMR guidance endorses for your cancer type, stage, and individual profile.

Who makes the decision — and how?

Your oncologist makes the decision, applying national and international guidelines to your specific case. The guidelines — from NCCN, ESMO, and ICMR — list the regimens with the strongest evidence base for each cancer type and stage.

Complex cases are reviewed by a multidisciplinary tumour board, where oncologists, radiologists, surgeons, and other specialists discuss the plan together. What looks like one doctor's recommendation is usually a team decision.

You can ask your oncologist to name your regimen, list its component drugs, and explain why that combination was chosen over others. A clear answer to all three is reasonable to expect at any appointment.

Who is not given these regimens?

Chemotherapy regimens are not given to everyone with cancer. Each regimen has specific contraindications based on its component drugs, and eligibility is always decided by an oncologist on the individual case.

You may not be a candidate for a particular regimen if you have:

Severely reduced kidney or liver function, which affects how certain drugs are cleared from the body
Significantly reduced heart function, which rules out anthracycline-containing regimens such as AC or R-CHOP
Very low blood counts at baseline, which increase the risk of serious infection
A documented severe allergy to a component drug
Pregnancy — most regimens carry risk to the developing fetus, though individual decisions are made with specialist guidance
An active, uncontrolled infection that requires treatment before chemotherapy can safely begin

Being unsuitable for one regimen does not mean you are unsuitable for all. Your oncologist will identify which options remain available for you.

Can your regimen change after treatment starts?

Yes. Treatment is reviewed after each response assessment — usually imaging after a typical number of cycles. If the cancer is responding, the same regimen generally continues. If it is not, a different one may be started.

Side effects can also prompt a change. If a particular drug is affecting your kidneys, heart, or nerves, your oncologist may remove or substitute it rather than stop treatment entirely.

A regimen change is a clinical adjustment, not a sign that treatment has failed. It is the same process of matching your current situation to the best available evidence.

Which regimen is used for which cancer type?

Breast cancer

AC (doxorubicin and cyclophosphamide) is commonly used, often followed by paclitaxel or docetaxel. In HER2-positive disease, trastuzumab — a targeted antibody — is added alongside chemotherapy. CMF (cyclophosphamide, methotrexate, fluorouracil) may be used in some contexts. The regimen depends on the molecular subtype, stage, and whether treatment is given before or after surgery.

Colorectal cancer

FOLFOX (fluorouracil, leucovorin, oxaliplatin) and CAPOX (capecitabine, oxaliplatin) are widely used. FOLFIRI (fluorouracil, leucovorin, irinotecan) is used when oxaliplatin is not suitable. Targeted agents such as bevacizumab or cetuximab may be added depending on RAS mutation testing and other tumour markers. Stage and the presence of metastases determine which regimen is appropriate.

Lymphoma

R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) is the standard for most B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma. ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is standard for Hodgkin lymphoma. The typical number of cycles is described as a range in NCCN and ESMO guidelines and varies with stage and response.

Lung cancer

Carbo-Taxol (carboplatin, paclitaxel) is commonly used in non-small cell lung cancer, sometimes alongside immunotherapy. Cisplatin and etoposide is standard for small cell lung cancer. GemCis (gemcitabine, cisplatin) is used in some subtypes. Molecular testing — for EGFR, ALK, ROS1, and PD-L1 — often determines whether targeted therapy replaces or accompanies chemotherapy.

Stomach and oesophageal cancer

ECF (epirubicin, cisplatin, fluorouracil) has been a longstanding regimen for these cancers. FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) is used in fit patients in perioperative settings per ESMO guidance. CAPOX (capecitabine, oxaliplatin) is also used. HER2 testing is performed on gastric cancer tissue, and trastuzumab may be added if overexpression is confirmed.

Germ cell tumours

BEP (bleomycin, etoposide, cisplatin) is the standard regimen for testicular cancer and most germ cell tumours. The number of cycles depends on the risk category established at diagnosis. EP (etoposide and cisplatin, without bleomycin) may be used when bleomycin is contraindicated, particularly in patients with lung concerns.

Did you know?

Most regimen acronyms come from brand names rather than generic drug names — the 'A' in both AC and ABVD stands for Adriamycin, the original brand name for doxorubicin. The same drug can appear under a different letter in a different regimen.

Source: NCCN Clinical Practice Guidelines in Oncology

Explore 82 more How Chemotherapy Is Given: Regimens, Cycles & Infusion Days topics

Chemotherapy Regimens by Name

Cycle Delays, Dose Reductions & Changes

HUB — Chemotherapy Regimens

Chemotherapy Regimens: What the Acronyms Mean

HUB — Cycles, Schedules and What Happens on Infusion Day

Cycles, Schedules and What Happens on Infusion Day

How Chemotherapy Is Given

Regimens, Cycles & Schedules

The Infusion Day

Your Chemotherapy Day, Hour by Hour

Your First Cycle

Your First Chemotherapy Cycle: What Happens

All How Chemotherapy Is Given: Regimens, Cycles & Infusion Days →

Common questions

Frequently asked questions

Why do two people with the same cancer get different regimens?

Regimen choice depends on far more than the cancer name. The molecular subtype, stage, organ function, and previous treatments all narrow or change the options. Someone with early breast cancer and someone with metastatic breast cancer will typically receive different regimens even though both have the same diagnosis. HER2-positive breast cancer requires different drugs from triple-negative disease. Your oncologist chose your specific regimen because of your tumour biology and your clinical profile, not the label on the diagnosis.

How do I find out what drugs I am actually on?

Ask your oncologist or the ward pharmacist to name each drug in your regimen and write them down for you. You are entitled to that information. Your treatment chart, the labels on your infusion bags, and your discharge summary all document what you are receiving. If you are given printed materials at the start of treatment, check whether they list each drug individually — many oncology teams provide this as a matter of routine.

How many cycles of chemotherapy will I need?

The number varies by regimen, cancer type, and treatment goal. NCCN and ESMO guidelines describe typical ranges rather than fixed numbers, and your plan may be adjusted based on response and tolerance. Your oncologist will tell you the planned number at the start and reassess after each response check. The number can change — in either direction — depending on what the imaging and blood results show at each review.

Can I ask to switch to a different regimen I have read about?

You can ask about any regimen you have read about, and your oncologist should explain why your current one was chosen. The decision to change is always a clinical one — not one that follows from internet research alone. A different regimen may be indicated only for a different subtype or stage, or it may carry a very different side-effect profile that is not appropriate for you. Bring what you have read to your next appointment and go through it together.

Why does the same regimen appear for more than one cancer type?

Several chemotherapy drugs work through general mechanisms — blocking DNA replication or disrupting cell division — that make them active across multiple cancer types. Carboplatin and paclitaxel, for example, are used in lung, ovarian, and endometrial cancers. The acronym may be the same, but the supporting drugs, the doses adjusted for body surface area and organ function, and the number of cycles will differ. The regimen name is a starting point, not a complete description of your treatment plan.

How do I know if my regimen is the one guidelines recommend?

Ask your oncologist which guideline your regimen comes from — NCCN, ESMO, and ICMR all publish regimen recommendations by cancer type and stage, and these are updated regularly as evidence changes. If a less common choice has been made because of your organ function, a rare subtype, or clinical trial eligibility, your oncologist should be able to explain the reasoning clearly. Asking for the source guideline is a reasonable question at any appointment.

Full index